Français Japonais Chinois Allemand Néerlandais Espagnol Portugais

    News

    BYD chooses Hauts-de-France

    China’s BYD is investing over €10 million in an electric bus assembly plant in Allonne, near Beauvais.

    Lille to host Emile animated film awards ceremony

    Hauts-de-France has been selected to host the first Emile Awards ceremony honoring Europe’s finest animated film. The distinction underscores its international reputation for animation know-how and position as...

    All news

    AstraZeneca ramps up investment in Dunkerque

    04 Nov 2013 | Investment, Health Nutrition

    AstraZeneca will invest €26 million in a new production line for the Symbicourt asthma inhaler at its Dunkerque plant. Existing lines will also be upgraded.

    AstraZeneca -  pharmaceutical laboratory - Symbicort - health - Lille Region

                Present in Dunkerque for over 20 years, pharmaceutical giant AstraZeneca has invested some €500 million in its local plant to date—outlays that reflect the facility’s strategic importance as the world’s sole producer of Symbicort inhalers. With demand for the asthma remedy on the rise, the plant needed new capacity. “The aerosol technology we use for this inhaler is fairly unique within our group, and is concentrated at Dunkerque,” says Plant Manager Dominique Bretaudeau.

                The plant, which exports 95% of its total output to the United States, has a long tradition of meeting challenges and adapting to changing patient needs. In addition to special projects, it invests around €2.5 million a year to upgrade and maintain equipment, enhance patient safety and improve packaging.

                AstraZeneca is one of the world’s top pharmaceutical companies and ranks fifth in the field in France. Its medicines cover six main therapeutic areas: cardiovascular & metabolic, infection, gastrointestinal, oncology, neurosciences and respiratory ailments. Sales total around $28 billion, with over $4 million invested in R&D each year.

     

    Source: AstraZeneca / Press

    Back to news